Vatalanib (BioDeep_00000720010)
代谢物信息卡片
Vatalanib base
化学式: C20H15ClN4 (346.0985)
中文名称: 伐拉尼布
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4
InChI: InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:90620
- KEGGdrug: D06285
- PubChem: 151194
- DrugBank: DB04879
- ChEMBL: CHEMBL101253
- CAS: 212141-54-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Bibian M E Tullemans, Alicia Veninga, Delia I Fernandez, Maureen J B Aarts, Johannes A Eble, Paola E J van der Meijden, Johan W M Heemskerk, Marijke J E Kuijpers. Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
International journal of molecular sciences.
2021 Oct; 22(20):. doi:
10.3390/ijms222011199. [PMID: 34681859] - Anne M Filppula, Tiffany M Mustonen, Janne T Backman. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Basic & clinical pharmacology & toxicology.
2018 Dec; 123(6):739-748. doi:
10.1111/bcpt.13088. [PMID: 29956478] - Xing Yuan, Lin Han, Peng Fu, Huawu Zeng, Chao Lv, Wanlin Chang, R Scott Runyon, Momoko Ishii, Liwen Han, Kechun Liu, Taiping Fan, Weidong Zhang, Runhui Liu. Cinnamaldehyde accelerates wound healing by promoting angiogenesis via up-regulation of PI3K and MAPK signaling pathways.
Laboratory investigation; a journal of technical methods and pathology.
2018 06; 98(6):783-798. doi:
10.1038/s41374-018-0025-8. [PMID: 29463877] - Xiaofeng Wang, Kouros Owzar, Pankaj Gupta, Richard A Larson, Flora Mulkey, Antonius A Miller, Lionel D Lewis, David Hurd, Ravi Vij, Mark J Ratain, Daryl J Murry. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
British journal of clinical pharmacology.
2014 Nov; 78(5):1005-13. doi:
10.1111/bcp.12427. [PMID: 24838014] - Rhonda L Bitting, Patrick Healy, Patricia A Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I Hurwitz, Mark D Starr, Andrew B Nixon, Andrew J Armstrong, Daniel J George. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Clinical genitourinary cancer.
2014 Aug; 12(4):241-50. doi:
10.1016/j.clgc.2013.11.020. [PMID: 24685058] - Y Ji, S Chen, K Li, X Xiao, T Xu, S Zheng. Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells.
The British journal of dermatology.
2014 Jan; 170(1):78-86. doi:
10.1111/bjd.12592. [PMID: 24033364] - Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Dec; 40(12):2332-41. doi:
10.1124/dmd.112.047068. [PMID: 22961681] - Thierry Jahan, Lin Gu, Robert Kratzke, Arkadiusz Dudek, Gregory A Otterson, Xiaofei Wang, Mark Green, Everett E Vokes, Hedy Lee Kindler. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
Lung cancer (Amsterdam, Netherlands).
2012 Jun; 76(3):393-6. doi:
10.1016/j.lungcan.2011.11.014. [PMID: 22197613] - Juefang Ding, Xiaoyan Chen, Xiaojian Dai, Dafang Zhong. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 May; 895-896(?):108-15. doi:
10.1016/j.jchromb.2012.03.027. [PMID: 22503745] - Marek Dziadosz, Rüdiger Lessig, Heidemarie Bartels. HPLC-DAD protein kinase inhibitor analysis in human serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Apr; 893-894(?):77-81. doi:
10.1016/j.jchromb.2012.02.037. [PMID: 22425385] - B Benjamin, M Sahu, U Bhatnagar, D Abhyankar, N R Srinivas. The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?.
Arzneimittel-Forschung.
2012 Apr; 62(4):194-201. doi:
10.1055/s-0031-1299772. [PMID: 22290114] - Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, Deborah Schrag, Peter C Enzinger, Jennifer A Chan, Matthew H Kulke, Brian M Wolpin, Michael Goldstein, Lawrence Blaszkowsky, Andrew X Zhu, Meaghan Elliott, Eileen Regan, Rakesh K Jain, Dan G Duda. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PloS one.
2012; 7(6):e38231. doi:
10.1371/journal.pone.0038231. [PMID: 22701615] - Chandrajit P Raut, Yves Boucher, Dan G Duda, Jeffrey A Morgan, Richard Quek, Marek Ancukiewicz, Johanna Lahdenranta, J Paul Eder, George D Demetri, Rakesh K Jain. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
PloS one.
2012; 7(2):e26331. doi:
10.1371/journal.pone.0026331. [PMID: 22347360] - Luis R de Brito, Mike A Batey, Yan Zhao, Matt S Squires, Helen Maitland, Hing Y Leung, Andrew G Hall, Graham Jackson, David R Newell, Julie A E Irving. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Leukemia research.
2011 Sep; 35(9):1233-40. doi:
10.1016/j.leukres.2011.01.011. [PMID: 21316102] - Michael I Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C Gatter, Tanja Trarbach, Gunnar Folprecht, Michael M Shi, David Lebwohl, Tarja Jalava, Dirk Laurent, Gerold Meinhardt, Adrian L Harris. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011 Jul; 17(14):4892-900. doi:
10.1158/1078-0432.ccr-10-2918. [PMID: 21632858] - Sandra R Brave, Rajesh Odedra, Neil H James, Neil R Smith, Gayle B Marshall, Kerry L Acheson, Dawn Baker, Zoe Howard, Lynsay Jackson, Kirsty Ratcliffe, Anna Wainwright, Susan C Lovick, D Mark Hickinson, Robert W Wilkinson, Simon T Barry, Georgina Speake, Anderson J Ryan. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
International journal of oncology.
2011 Jul; 39(1):271-8. doi:
10.3892/ijo.2011.1022. [PMID: 21537841] - Elizabeth R Gerstner, April F Eichler, Scott R Plotkin, Jan Drappatz, Colin L Doyle, Lei Xu, Dan G Duda, Patrick Y Wen, Rakesh K Jain, Tracy T Batchelor. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Journal of neuro-oncology.
2011 Jun; 103(2):325-32. doi:
10.1007/s11060-010-0390-7. [PMID: 20821342] - J Randolph Hecht, Tanja Trarbach, John D Hainsworth, Pierre Major, Elke Jäger, Robert A Wolff, Katherine Lloyd-Salvant, György Bodoky, Kelly Pendergrass, William Berg, Bee-Lian Chen, Tarja Jalava, Gerold Meinhardt, Dirk Laurent, David Lebwohl, David Kerr. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011 May; 29(15):1997-2003. doi:
10.1200/jco.2010.29.4496. [PMID: 21464406] - Monika Wnuk, Ruslan Hlushchuk, Gérald Tuffin, Uyen Huynh-Do, Valentin Djonov. The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRβ pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis.
The American journal of pathology.
2011 Apr; 178(4):1899-912. doi:
10.1016/j.ajpath.2010.12.049. [PMID: 21435466] - Pankaj Bhargava, Murray O Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Current oncology reports.
2011 Apr; 13(2):103-11. doi:
10.1007/s11912-011-0154-3. [PMID: 21318618] - Terence O'Reilly, Heidi A Lane, Jeanette M Wood, Christian Schnell, Amanda Littlewood-Evans, Josef Brueggen, Paul M J McSheehy. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
Cancer chemotherapy and pharmacology.
2011 Jan; 67(1):193-200. doi:
10.1007/s00280-010-1307-z. [PMID: 20512579] - Y Wang. Everolimus in renal cell carcinoma.
Drugs of today (Barcelona, Spain : 1998).
2010 Aug; 46(8):557-66. doi:
10.1358/dot.2010.46.8.1516824. [PMID: 20830316] - Agnes Jaeger-Lansky, Daniel Cejka, Liu Ying, Matthias Preusser, Doris Hoeflmayer, Thorsten Fuereder, Stefan Koehrer, Volker Wacheck. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Cancer biology & therapy.
2010 Jun; 9(11):919-27. doi:
10.4161/cbt.9.11.11805. [PMID: 20404549] - Astrid A M van der Veldt, Martijn R Meijerink, Alfons J M van den Eertwegh, Epie Boven. Targeted therapies in renal cell cancer: recent developments in imaging.
Targeted oncology.
2010 Jun; 5(2):95-112. doi:
10.1007/s11523-010-0146-5. [PMID: 20625845] - Meser M Ali, Branislava Janic, Abbas Babajani-Feremi, Nadimpalli R S Varma, A S M Iskander, John Anagli, Ali S Arbab. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
PloS one.
2010 Jan; 5(1):e8727. doi:
10.1371/journal.pone.0008727. [PMID: 20090952] - N Murukesh, C Dive, G C Jayson. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.
British journal of cancer.
2010 Jan; 102(1):8-18. doi:
10.1038/sj.bjc.6605483. [PMID: 20010945] - A G Lankheet, M J X Hillebrand, M H G Langenberg, H Rosing, A D R Huitema, E E Voest, J H M Schellens, J H Beijnen. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Nov; 877(29):3625-30. doi:
10.1016/j.jchromb.2009.09.001. [PMID: 19762293] - David A Reardon, Merrill J Egorin, Annick Desjardins, James J Vredenburgh, Jan H Beumer, Theodore F Lagattuta, Sridharan Gururangan, James E Herndon, August J Salvado, Henry S Friedman. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Cancer.
2009 May; 115(10):2188-98. doi:
10.1002/cncr.24213. [PMID: 19248046] - Heidi A Lane, Jeanette M Wood, Paul M J McSheehy, Peter R Allegrini, Anne Boulay, Joseph Brueggen, Amanda Littlewood-Evans, Sauveur-Michel Maira, Georg Martiny-Baron, Christian R Schnell, Patrizia Sini, Terence O'Reilly. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009 Mar; 15(5):1612-22. doi:
10.1158/1078-0432.ccr-08-2057. [PMID: 19223496] - Cedric de Bazelaire, David C Alsop, Daniel George, Ivan Pedrosa, Yongyu Wang, M Dror Michaelson, Neil M Rofsky. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Sep; 14(17):5548-54. doi:
10.1158/1078-0432.ccr-08-0417. [PMID: 18765547] - M Vaughn Emerson, Andreas K Lauer. Current and emerging therapies for the treatment of age-related macular degeneration.
Clinical ophthalmology (Auckland, N.Z.).
2008 Jun; 2(2):377-88. doi:
10.2147/opth.s1485. [PMID: 19668729] - Niina K Malmström, Erkki A Kallio, Jukka M Rintala, Antti I Nykänen, Anne K Räisänen-Sokolowski, Timo Paavonen, Karl B Lemström, Petri K Koskinen. Vascular endothelial growth factor in chronic rat allograft nephropathy.
Transplant immunology.
2008 May; 19(2):136-44. doi:
10.1016/j.trim.2008.01.009. [PMID: 18503889] - M Vaughn Emerson, Andreas K Lauer. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
2007; 21(4):245-57. doi:
10.2165/00063030-200721040-00005. [PMID: 17628122] - Lorenz M Jost, Hans-Peter Gschwind, Tarja Jalava, Yongyu Wang, Clemens Guenther, Claire Souppart, Antje Rottmann, Karsten Denner, Felix Waldmeier, Gerhard Gross, Eric Masson, Dirk Laurent. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
Drug metabolism and disposition: the biological fate of chemicals.
2006 Nov; 34(11):1817-28. doi:
10.1124/dmd.106.009944. [PMID: 16882767] - Lucy Lee, Sunil Sharma, Bruno Morgan, Peter Allegrini, Christian Schnell, Josef Brueggen, Robert Cozens, Mark Horsfield, Clemens Guenther, Will P Steward, Joachim Drevs, David Lebwohl, Jeanette Wood, Paul M J McSheehy. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Cancer chemotherapy and pharmacology.
2006 Jun; 57(6):761-71. doi:
10.1007/s00280-005-0120-6. [PMID: 16172907] - Allan Wissner, M Brawner Floyd, Bernard D Johnson, Heidi Fraser, Charles Ingalls, Thomas Nittoli, Russell G Dushin, Carolyn Discafani, Ramaswamy Nilakantan, Joseph Marini, Malini Ravi, Kinwang Cheung, Xingzhi Tan, Sylvia Musto, Tami Annable, Marshall M Siegel, Frank Loganzo. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Journal of medicinal chemistry.
2005 Dec; 48(24):7560-81. doi:
10.1021/jm050559f. [PMID: 16302797] - Yasuhide Kitagawa, Jinlu Dai, Jian Zhang, Jill M Keller, Jacques Nor, Zhi Yao, Evan T Keller. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Cancer research.
2005 Dec; 65(23):10921-9. doi:
10.1158/0008-5472.can-05-1809. [PMID: 16322239] - J Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, K Mross, M Medinger, L Lee, J Pinheiro, J Wood, A L Thomas, C Unger, A Henry, W P Steward, D Laurent, D Lebwohl, M Dugan, D Marmé. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
Annals of oncology : official journal of the European Society for Medical Oncology.
2005 Apr; 16(4):558-65. doi:
10.1093/annonc/mdi118. [PMID: 15705616] - Holger Hess-Stumpp, Martin Haberey, Karl-Heinz Thierauch. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Chembiochem : a European journal of chemical biology.
2005 Mar; 6(3):550-7. doi:
10.1002/cbic.200400305. [PMID: 15742376] - Cedric De Bazelaire, Neil M Rofsky, Guillaume Duhamel, M Dror Michaelson, Daniel George, David C Alsop. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
Academic radiology.
2005 Mar; 12(3):347-57. doi:
10.1016/j.acra.2004.12.012. [PMID: 15766695] - Bruno Morgan, Anne L Thomas, Joachim Drevs, Juergen Hennig, Martin Buchert, Asvina Jivan, Mark A Horsfield, Klaus Mross, Howard A Ball, Lucy Lee, William Mietlowski, Stefan Fuxuis, Clemens Unger, Ken O'Byrne, Andrew Henry, Graham R Cherryman, Dirk Laurent, Margaret Dugan, Dieter Marmé, William P Steward. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2003 Nov; 21(21):3955-64. doi:
10.1200/jco.2003.08.092. [PMID: 14517187] - Karl Turetschek, Anda Preda, Eugenia Floyd, David M Shames, Viktor Novikov, Timothy P L Roberts, Jeanette M Wood, Yanjun Fu, Wayne O Carter, Robert C Brasch. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
European journal of nuclear medicine and molecular imaging.
2003 Mar; 30(3):448-55. doi:
10.1007/s00259-002-1000-5. [PMID: 12722742] - Joachim Drevs, Ralph Müller-Driver, Christine Wittig, Stefan Fuxius, Norbert Esser, Harald Hugenschmidt, Moritz A Konerding, Peter R Allegrini, Jeanette Wood, Jürgen Hennig, Clemens Unger, Dieter Marmé. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Cancer research.
2002 Jul; 62(14):4015-22. doi:
NULL. [PMID: 12124335] - J Drevs, I Hofmann, H Hugenschmidt, C Wittig, H Madjar, M Müller, J Wood, G Martiny-Baron, C Unger, D Marmé. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Cancer research.
2000 Sep; 60(17):4819-24. doi:
NULL. [PMID: 10987292] - J M Wood, G Bold, E Buchdunger, R Cozens, S Ferrari, J Frei, F Hofmann, J Mestan, H Mett, T O'Reilly, E Persohn, J Rösel, C Schnell, D Stover, A Theuer, H Towbin, F Wenger, K Woods-Cook, A Menrad, G Siemeister, M Schirner, K H Thierauch, M R Schneider, J Drevs, G Martiny-Baron, F Totzke. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Cancer research.
2000 Apr; 60(8):2178-89. doi:
. [PMID: 10786682] - J M Wood. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Medicina.
2000; 60 Suppl 2(?):41-7. doi:
. [PMID: 11188930]
